Published: Jul 8, 2026
Written by Klarity Editorial Team
Published: Jul 8, 2026

You’re a psychiatrist watching half your patients struggle with weight gain from their meds. You’re seeing the GLP-1 craze explode on social media. And you’re thinking: Should I be doing this?
Short answer: Yes. And here’s why it makes business sense.
By 2025, an estimated 6% of Americans—20 million people—were actively taking GLP-1 drugs like Ozempic or Wegovy. That’s a 600% increase in weight-loss usage over six years. The demand is massive, the patient pool overlaps perfectly with your existing practice, and the revenue model actually works.
But here’s the thing nobody talks about: scaling a GLP-1 practice the wrong way will wreck you. You’ll drown in follow-ups, burn out on admin work, and wonder why you ever left traditional psychiatry.
This guide walks through how to build a sustainable, profitable GLP-1 service line as a psychiatrist—without sacrificing your weekends or your sanity.
Nearly half of psychiatrists surveyed in late 2023 were already prescribing or recommending Ozempic or similar weight-loss drugs. Why? Because antipsychotics, mood stabilizers, and some antidepressants cause significant weight gain—and patients hate it.
You’re not pivoting to a new specialty. You’re solving a problem that’s been sitting in your waiting room the whole time.
Unlike a random telehealth provider cranking out prescriptions, you bring behavioral expertise. You understand motivation, mood changes, binge eating, and the psychological side of sustainable weight loss. That’s a competitive advantage the ‘Ozempic mills’ don’t have.
Many of your patients dealing with depression, anxiety, or binge eating disorder are also struggling with obesity. Addressing both simultaneously improves outcomes—and patients will pay for that integrated care.
Some early research even suggests GLP-1s might independently improve certain psychiatric symptoms. While that’s still being studied, what’s clear is that helping a patient lose 15-20% of their body weight often improves their self-image, energy, and overall mental health.
That’s the kind of holistic care that builds loyalty and referrals.
Here’s the brutal truth about insurance and weight-loss drugs: most plans don’t cover them.
As of mid-2024, only 13 state Medicaid programs (including California, Pennsylvania, and Illinois) covered GLP-1s for weight loss. Private insurance? Even worse—most exclude obesity drugs entirely or require impossibly high BMI thresholds and prior authorization battles.
The result: most patients are paying out-of-pocket anyway, whether it’s for branded Wegovy ($1,300+/month) or compounded semaglutide (often $200-400/month through telehealth pharmacies).
This creates a natural cash-pay market. Patients expect to pay. They’re willing to pay. And you avoid the prior authorization nightmare.
Most successful GLP-1 practices charge:
Some providers bundle this into monthly subscription packages ($200-400/month including medication and visits). Others charge per visit and let patients handle their own pharmacy relationship.
The key: transparency. Tell patients upfront what they’ll pay for visits and give them realistic medication cost estimates.
If you want to accept insurance for visits (while patients still pay cash for meds), you can bill standard E/M codes for obesity management or use Medicare’s G0447 code for behavioral obesity counseling.
This widens your patient pool but brings the usual headaches: documentation requirements, potential denials, and the need for careful coordination with pharmacies on prior authorizations.
A hybrid model works well: charge cash for comprehensive initial consults (which insurance reimburses poorly anyway), but bill insurance for routine follow-ups if the patient has good coverage.
The tide may be turning—Medicare announced pilot programs in late 2025 to start covering weight-loss drugs. If that expands, an insurance-based model might become more viable long-term.
The easiest patients to convert are the ones you’re already treating.
Identify patients with:
Bring it up during med checks: ‘We’ve had good success helping patients lose weight gained from medications. Would you be interested in discussing that?’
No additional marketing spend. Just serving the need that’s already there.
Once you’ve tapped your existing panel, here’s how to attract new weight-loss patients:
Telehealth Platforms
Join established platforms (like Klarity Health) that are already spending thousands per month on patient acquisition. They handle the marketing, you get pre-qualified patient leads, and you only pay when someone books with you.
This is the lowest-risk path to volume. Instead of gambling $3,000-5,000/month on Google Ads and SEO (which takes 6-12 months to generate results), you pay per appointment and get guaranteed ROI from day one.
Reality check: acquiring a qualified psychiatric patient through DIY marketing typically costs $200-500+ per patient when you factor in ad spend, agency fees, staff time to handle leads, no-show rates, and months of investment before you see results. Most solo providers don’t have the budget, expertise, or patience for that.
SEO & Content Marketing
If you want to build your own funnel long-term, create content around:
This takes 6-12 months of consistent investment but can eventually generate organic patient flow.
Social Media
Share success stories (with permission), educate about the mental health-obesity connection, and position yourself as the provider who understands both sides of the equation.
Referral Relationships
Let local PCPs, endocrinologists, therapists, and dietitians know you’re offering this service. Emphasize you’ll collaborate and refer patients back for ongoing primary care.
Prescribing GLP-1s via telehealth is legal in all 50 states—these are not controlled substances, so Ryan Haight Act restrictions don’t apply. But licensing and scope of practice rules vary significantly by state.
Here’s where most providers screw up: they try to scale by seeing more patients without changing their workflow. That’s a recipe for exhaustion.
Use digital intake forms to collect comprehensive history before the first appointment:
Create standardized order sets: ‘GLP-1 Baseline Labs’ (A1c, TSH, liver panel, lipids) that you can order with one click.
Develop inclusion/exclusion checklists so your intake staff can screen patients before they reach you.
This cuts your initial consult from 60 minutes to 30 minutes because you’re not gathering basic info—you’re making clinical decisions.
Patients typically need monthly follow-ups during the first 3-6 months for:
Once stable on a maintenance dose, you can space visits to every 2-3 months with brief virtual check-ins or asynchronous updates between visits.
You don’t need to do every task yourself:
By delegating non-specialist tasks, you focus on medication decisions and complex cases—not tech support or meal planning debates.
Use a telehealth-friendly EHR with:
Consider remote patient monitoring: connected scales or simple weekly weight check-ins via app let you track progress at a glance and intervene only when needed.
Some practices use AI chatbots for FAQs (‘Is nausea normal?’ ‘What do I do if I miss a dose?’)—freeing up staff time.
Watch for:
If these appear, pause new intakes, hire support staff, or bring on a part-time PMHNP/PA to share the load.
Scaling means growing the practice, not just your personal patient count. Some providers hit their limit at 150-200 active GLP-1 patients; others build teams and manage 500+. Know your capacity and build accordingly.
Patients think GLP-1s are magic pills. They’re not. Weight loss requires medication plus behavioral change.
Fix: In your initial consult, emphasize that GLP-1s are tools to improve health, not vanity drugs. Discuss realistic weight loss timelines (5-15% over 6-12 months), the need for diet and exercise, and the possibility of plateaus.
Patients who understand this upfront have better outcomes and are less likely to ghost you when results slow.
In 2023, there were reports of suicidal ideation possibly linked to GLP-1s. The FDA later reviewed data and found no clear causal link (even directing removal of suicide warnings from labels in early 2026), but psychiatrists should still stay vigilant.
Fix: At every follow-up, ask about mood, anxiety, or intrusive thoughts. You’re uniquely qualified to catch this—it’s a competitive advantage.
Many telehealth practices use compounding pharmacies to provide lower-cost semaglutide. Some of these are sketchy—the FDA has issued warnings about unregulated compounders.
Fix: Partner only with properly licensed, vetted compounding pharmacies (or stick with FDA-approved medications like Wegovy/Saxenda). If a pharmacy can’t provide clear documentation of their ingredients and quality control, walk away.
You can’t scale a high-volume GLP-1 practice solo while maintaining a full psychiatric caseload.
Fix: Hire support staff, use templates and automation, and consider a group practice model where you supervise PMHNPs who handle routine follow-ups while you focus on complex cases.
Let’s talk numbers.
Traditional DIY Marketing:
Platform Model (e.g., Klarity):
The math is simple: Instead of spending $3,000-5,000/month gambling on marketing channels, you pay per appointment and get guaranteed ROI.
For most providers—especially those starting out or scaling—removing the patient acquisition risk entirely is the smart economic choice.
Can psychiatric NPs prescribe GLP-1s independently?
Depends on the state. In states like New York (after 3,600 hours), Illinois (after 4,000 hours + coursework), and California (starting 2026 for 104 NPs), experienced PMHNPs can practice independently. In Texas, Florida, and Pennsylvania, NPs need physician supervision/collaboration to prescribe.
Do I need malpractice insurance for GLP-1 prescribing?
Yes. Inform your malpractice carrier that you’re prescribing weight-loss medications. This may be considered a separate risk category, but it generally falls within general practice for physicians.
How much can I realistically earn from a GLP-1 service line?
If you see 10 new weight-loss patients per month at $200/initial consult ($2,000) plus 30 monthly follow-ups at $100 each ($3,000), that’s $5,000/month in additional revenue—before accounting for medication markup or subscription models. Scale to 50-100 active patients and you’re looking at $10,000-15,000+ monthly.
What if a patient has psychiatric side effects on GLP-1s?
Document thoroughly, adjust the dose or discontinue if needed, and consider whether their underlying psychiatric condition is worsening independently. Your psychiatric expertise is the safety net here—most weight-loss providers would refer out; you can manage it in-house.
Can I prescribe GLP-1s to out-of-state patients?
Only if you’re licensed in that state. Some states (like Florida) offer streamlined telehealth registration for out-of-state providers. Otherwise, you need full licensure or use interstate compacts (IMLC for physicians) to practice across state lines.
What happens when patients reach their goal weight?
Most will need ongoing maintenance therapy (often at a lower dose) to prevent regain. Some can transition off medication with intensive behavioral support, but current evidence suggests most patients regain weight after stopping GLP-1s. Set this expectation early.
Here’s the roadmap:
The GLP-1 opportunity is real. The demand is massive. And as a psychiatrist, you bring clinical depth that most weight-loss providers don’t have.
Done right, this isn’t just a revenue add-on—it’s a chance to deliver holistic, life-changing care to patients who desperately need it.
Ready to add GLP-1 services to your practice? Join Klarity Health’s provider network and start seeing pre-qualified weight-loss patients this week—no marketing spend required.
Axios – ‘Just how many Americans are taking GLP-1s now’ (Fair Health data on usage). May 27, 2025. www.axios.com
ConfectioneryNews – ‘GLP-1 drugs like Ozempic are reshaping health, diet and the food industry.’ October 20, 2025. www.confectionerynews.com
PharmaNewsIntelligence – ‘Psychiatrists Prescribe or Recommend Ozempic for Weight Loss’ (via forum discussion). November 6, 2023. forum.schizophrenia.com
Axios – ‘America’s doctors need more obesity medicine training.’ May 28, 2024. www.axios.com
Axios – ‘States slow to cover GLP-1s for weight loss’ (KFF policy report). November 5, 2024. www.axios.com
Find the right provider for your needs — select your state to find expert care near you.